Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?

Reflections from the 2021 OARSI clinical trial symposium: Considerations for understanding biomarker assessments in osteoarthritis drug development - Should future studies focus on disease activity, rather than status?

Objective: Osteoarthritis (OA) is heterogeneous disease, for which drug development has proven to be challenging, both facilitated and hampered by changing guidelines. This is evident by the current lack of approved treatments, which improve joint function and delay joint failure. There is a need to...

Full description

Bibliographic Details
Main Authors: M.A. Karsdal, J. Tambiah, M.C. Hochberg, C. Ladel, A.C. Bay-Jensen, L. Arendt-Nielsen, A. Mobasheri, V.B. Kraus
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:Osteoarthritis and Cartilage Open
Subjects:
Osteoarthritis
Drug development
Clinical trial
Online Access:http://www.sciencedirect.com/science/article/pii/S2665913122000309

Similar Items

Similar Items